Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Uro-Oncology
Related content
Uro-Oncology
Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison
Adv Ther
Chowdhury S, Oudard S, Uemura H, Joniau S, Dearden L, Capone C, Van Sanden S, Diels J, Hadaschik BA
doi: 10.1007/s12325-021-01885-6
COMMENTED
Uro-Oncology
New Anti-Androgen Compounds Compared to Docetaxel in Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis
★ 2
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
J Urol.
Marchioni M, Di Nicola M, Primiceri G, Novara G, Castellan P, Paul A, Veccia A, Autorino R, Cindolo L, Schips L
doi: 10.1097/JU.0000000000000636.
Uro-Oncology
Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis
Eur Urol.
Sathianathen NJ, Koschel S, Thangasamy IA, Teh J, Alghazo O, Butcher G, Howard H, Kapoor J, Lawrentschuk N, Siva S, Azad A, Tran B, Bolton D, Murphy DG
doi: 10.1016/j.eururo.2019.09.004.
Further Publications UrologyFurther Publications Gynecology
Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data
Lancet.
Vale CL, Fisher D, Kneebone A, Parker C, Pearse M, Richaud P, Sargos P, Sydes MR, Brawley C, Brihoum M, Brown C, Chabaud S, Cook A, Forcat S, Fraser-Browne C, Latorzeff I, Parmar MKB, Tierney JF, ARTISTIC Meta-analysis Group.
doi: 10.1016/S0140-6736(20)31952-8.
Uro-Oncology
Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis
Eur Urol.
Burdett S, Boevé LM, Ingleby FC, Fisher DJ, Rydzewska LH, Vale CL, van Andel G, Clarke NW, Hulshof MC, James ND, Parker CC, Parmar MK, Sweeney CJ, Sydes MR, Tombal B, Verhagen PC, Tierney JF, STOPCAP M1 Radiotherapy Collaborators
doi: 10.1016/j.eururo.2019.02.003.
COMMENTED
Uro-Oncology
Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
doi: 10.1016/j.eururo.2020.01.033.
Uro-Oncology
Associations of fat and muscle mass with overall survival in men with prostate cancer: a systematic review with meta-analysis
Prostate Cancer Prostatic Dis
Lopez P, Newton RU, Taaffe DR, Singh F, Buffart LM, Spry N, Tang C, Saad F, Galvão DA
doi: 10.1038/s41391-021-00442-0
COMMENTED
Uro-Oncology
Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study
★ 2
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
★ 3
Recommended by
Alexander Meisel, Faculty Member
Eur Urol.
Thiery-Vuillemin A, Hvid Poulsen M, Lagneau E, Ploussard G, Birtle A, Dourthe LM, Beal-Ardisson D, Pintus E, Trepiakas R, Lefresne F, Lukac M, Van Sanden S, Pissart G, Reid A, AQUARiUS Investigators.
doi: 10.1016/j.eururo.2019.09.019.
Uro-Oncology
Systemic treatment for metastatic castrate resistant prostate cancer: Does seqence matter?
Prostate.
Andrews JR, Ahmed ME, Karnes RJ, Kwon E, Bryce AH
doi: 10.1002/pros.23954.